ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
ENANTA PHARMACEUTICALS INC
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.41+0.31 (+2.79%)
Close on Oct 19, 2026
- Market cap
- $331.92M
- P/E (TTM)
- –
- Dividend yield
- –
ENANTA PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q4 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty [Member] | $65.26M | $69.21M | $65.32M | $66.59M | $67.64M | $71.96M | $72.88M | $73.62M | $78.20M | $79.59M | $80.18M | $81.10M | 100.0% |
| License [Member] | – | – | – | – | $0 | $0 | $0 | $0 | $1.00M | $1.00M | $1.00M | $1.00M | – |
By region
From the segment and revenue-disaggregation notes of Enanta Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.